Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 117690-79-6 Chemical Structure| 117690-79-6

Structure of LY255283
CAS No.: 117690-79-6

Chemical Structure| 117690-79-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LY255283 is selective, competitive antagonist of BLT2 receptors (IC50 values are ~ 1 and > 10 μM at human recombinant BLT2 and BLT1 receptors respectively), and inhibits LTB4-induced contraction of lung parenchyma (pA2 = 7.2), and reduces LTB4-mediated airway obstruction in guinea pigs following i.v. and oral administration.

Synonyms: LY255283

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of LY255283

CAS No. :117690-79-6
Formula : C19H28N4O3
M.W : 360.45
SMILES Code : CC(C1=CC(CC)=C(OCCCCCC(C2=NNN=N2)(C)C)C=C1O)=O
Synonyms :
LY255283
MDL No. :MFCD00876422
InChI Key :WCGXJPFHTHQNJL-UHFFFAOYSA-N
Pubchem ID :122023

Safety of LY255283

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H228-H315-H319
Precautionary Statements:P240-P210-P241-P264-P280-P302+P352-P370+P378-P337+P313-P305+P351+P338-P362+P364-P332+P313
Class:4.1
UN#:1325
Packing Group:

Isoform Comparison

Biological Activity

Description
LY255283 is an antagonist to the LTB4 receptor (BLT2), demonstrating an IC50 of approximately 100 nM for blocking [3H]LTB4 binding in guinea pig lung membranes[1].[2].[3].[4].

In Vitro:

Cell Line
Concentration Treated Time Description References
Bone marrow-derived macrophages (BMDMs) 0.1–10 μM 1 or 4 hours To investigate the effect of LY255283 on phagocytosis of B. burgdorferi by BLT1−/− BMDMs. Results showed that LY255283 inhibited LTB4-mediated phagocytosis in a dose-dependent manner. J Lipid Res. 2017 Mar;58(3):494-503
IMR-90 human lung fibroblasts 50 nM 48 hours To assess the inhibitory effect of LT antagonists on COL1A2 mRNA expression JCI Insight. 2019 Dec 19;4(24):e130056
Caco-2 cells 25 µM 48 hours To investigate the effect of LY255283 on EPA-induced Caco-2 cell proliferation, results showed that LY255283 reversed the proliferative effect of EPA Front Pharmacol. 2020 Sep 4;11:529976

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rats Transient middle cerebral artery occlusion model Intraperitoneal injection 1 mg/kg Single dose, 10 min before tMCAO induction To evaluate the effect of LY255283 on brain infarct volume; results showed LY255283 reduced infarct volume by approximately 30% Neurotherapeutics. 2020 Jan;17(1):282-293

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.77mL

0.55mL

0.28mL

13.87mL

2.77mL

1.39mL

27.74mL

5.55mL

2.77mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories